KR102286115B1 - 경피 약물 전달용 이온성 액체 - Google Patents

경피 약물 전달용 이온성 액체 Download PDF

Info

Publication number
KR102286115B1
KR102286115B1 KR1020167014980A KR20167014980A KR102286115B1 KR 102286115 B1 KR102286115 B1 KR 102286115B1 KR 1020167014980 A KR1020167014980 A KR 1020167014980A KR 20167014980 A KR20167014980 A KR 20167014980A KR 102286115 B1 KR102286115 B1 KR 102286115B1
Authority
KR
South Korea
Prior art keywords
component
anion
composition
skin
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167014980A
Other languages
English (en)
Korean (ko)
Other versions
KR20160097202A (ko
Inventor
마이클 자크루스키
사미르 미트라고트리
데이비드 티. 폭스
앤드류 코피쉬
리코 델 세스토
케서린 러브조이
Original Assignee
더 리전츠 오브 더 유니버시티 오브 캘리포니아
로스 알라모스 내셔널 씨큐어리티 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리전츠 오브 더 유니버시티 오브 캘리포니아, 로스 알라모스 내셔널 씨큐어리티 엘엘씨 filed Critical 더 리전츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20160097202A publication Critical patent/KR20160097202A/ko
Application granted granted Critical
Publication of KR102286115B1 publication Critical patent/KR102286115B1/ko
Assigned to 더 아리조나 보드 오브 리전츠 포 앤드 온 비해프 오브 노던 아리조나 유니버시티 reassignment 더 아리조나 보드 오브 리전츠 포 앤드 온 비해프 오브 노던 아리조나 유니버시티 권리지분의 일부이전등록 Assignors: 로스 알라모스 내셔널 씨큐어리티 엘엘씨
Assigned to 트리아드 내셔널 시큐리티, 엘엘씨 reassignment 트리아드 내셔널 시큐리티, 엘엘씨 권리지분의 전부이전등록 Assignors: 로스 알라모스 내셔널 씨큐어리티 엘엘씨
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y10S514/857—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Insects & Arthropods (AREA)
KR1020167014980A 2013-11-03 2014-11-03 경피 약물 전달용 이온성 액체 Active KR102286115B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899294P 2013-11-03 2013-11-03
US61/899,294 2013-11-03
PCT/US2014/063745 WO2015066647A2 (en) 2013-11-03 2014-11-03 Ionic liquids for transdermal drug delivery

Publications (2)

Publication Number Publication Date
KR20160097202A KR20160097202A (ko) 2016-08-17
KR102286115B1 true KR102286115B1 (ko) 2021-08-04

Family

ID=53005413

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167014980A Active KR102286115B1 (ko) 2013-11-03 2014-11-03 경피 약물 전달용 이온성 액체

Country Status (7)

Country Link
US (3) US10449254B2 (https=)
EP (1) EP3062819B1 (https=)
JP (3) JP2016535781A (https=)
KR (1) KR102286115B1 (https=)
CA (2) CA2929630C (https=)
ES (1) ES2908345T3 (https=)
WO (1) WO2015066647A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
EP3395368A1 (en) * 2014-10-30 2018-10-31 Asahi Kasei Kabushiki Kaisha Transdermal absorption enhancer and transdermal absorption enhancement aid
CA2931913C (en) 2015-06-12 2024-03-19 Kemira Oyj Bitumen separation using ionic liquids comprising unsubstituted or substituted primary, secondary or tertiary amines, pyridines, amidines, guanidines and fatty acids and/or resin acids
JP7179354B2 (ja) * 2016-08-29 2022-11-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚処置のためのイオン種に基づく局所処方物
US11274137B1 (en) * 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery
US11213497B2 (en) 2017-06-01 2022-01-04 Arizona Board Of Regents On Behalf Of Northern Arizona University Antibiofilm formulations
CN111918644A (zh) * 2017-11-17 2020-11-10 哈佛大学校长及研究员协会 用于内部递送的离子液体
JP2019131480A (ja) * 2018-01-29 2019-08-08 旭化成株式会社 経皮吸収促進剤及び経皮製剤
EP3768240A4 (en) * 2018-03-19 2021-12-22 Cage Bio Inc. COMPOSITIONS OF IONIC LIQUID FOR THE TREATMENT OF ROSACEA
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR101959524B1 (ko) * 2018-09-19 2019-03-18 주식회사 우신라보타치 리도카인을 포함한 이온토포레시스용 점착성 카타플라스마 시스템
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
US20220257767A1 (en) 2019-04-03 2022-08-18 President And Fellows Of Harvard College Ionic liquids for drug delivery
EP3744312B1 (en) * 2019-05-29 2022-03-23 Assistance Publique, Hopitaux De Paris Green tea catechins eutectic system
CN115348858A (zh) * 2019-11-08 2022-11-15 凯奇生物公司 使用离子液体的托法替尼表面递送
WO2021102084A1 (en) 2019-11-22 2021-05-27 President And Fellows Of Harvard College Ionic liquids for drug delivery
WO2021119198A1 (en) * 2019-12-09 2021-06-17 Cage Bio, Inc. Topical delivery of rna interference agents using ionic liquid
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
WO2021263201A1 (en) * 2020-06-26 2021-12-30 Cage Bio Inc. Sanitizing compositions containing ionic liquid
US20230372273A1 (en) * 2020-10-05 2023-11-23 Cage Bio, Inc. Ionic liquid compositions for skin diseases and conditions
JP7284877B2 (ja) * 2020-10-29 2023-05-31 久光製薬株式会社 ロピニロール含有貼付剤及びロピニロールの皮膚透過性向上方法
WO2022101490A1 (en) * 2020-11-13 2022-05-19 Universidade Do Minho Eutectic compositions, methods and uses thereof
WO2022256291A1 (en) 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
US12005134B2 (en) 2021-06-30 2024-06-11 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth
CN118382429A (zh) 2021-10-08 2024-07-23 哈佛大学校长及研究员协会 用于药物递送的离子液体
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
CN116474153B (zh) * 2022-01-17 2024-09-27 四川大学 一种基于竹纤维-低共熔溶剂-明胶的皮肤溃疡护理贴膜
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
CN115671285B (zh) * 2022-08-24 2024-01-05 上海市皮肤病医院 一种抗真菌溶液及其制备方法和应用
WO2025147130A1 (ko) * 2024-01-03 2025-07-10 주식회사 바이온리퀴드 이온성 액체 또는 공융 용매를 이용한 신규 약물제형
WO2026041873A1 (en) * 2024-08-21 2026-02-26 The University Of Reading Compositions for systemic administration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031105A1 (en) 2006-09-08 2008-03-13 Delaval Holdings Ab Polymeric guanidine salt-based germicides
JP2008184402A (ja) 2007-01-29 2008-08-14 Medorekkusu:Kk 外用剤用の低刺激性溶解助剤
WO2011056545A2 (en) * 2009-10-26 2011-05-12 Trustees Of Boston University Antimicrobial ionic liquids

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342840A (en) * 1964-03-23 1967-09-19 Shell Oil Co Cationic ester production
US4042327A (en) 1976-01-15 1977-08-16 Waters Associates, Inc. Ion-pairing chromatography
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPS62209523A (ja) 1986-03-11 1987-09-14 Fuji Photo Film Co Ltd 感光材料
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
ZA952521B (en) * 1994-03-28 1996-03-15 Univ Columbia Composition for inactivating irritants in fluids
KR19990022598A (ko) 1995-06-07 1999-03-25 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 미셀 보호 분석법
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
ATE384554T1 (de) * 2001-12-21 2008-02-15 Rhodia Kombinierte stabile kationische und anionische tensidzusammensetzungen
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US6858217B2 (en) * 2002-03-22 2005-02-22 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stabilization of terpenoids in cosmetic compositions
DE602005010812D1 (de) 2004-11-22 2008-12-18 Hisamitsu Pharmaceutical Co Transdermales Pflaster enthaltend einen schmelzpunktsenkenden Hilfsstoff
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
EP2016056A4 (en) 2006-04-21 2010-11-10 Univ Boston IONIC VISCOELASTIC AND VISCOELASTIC SALTS
JP4952272B2 (ja) 2007-01-29 2012-06-13 株式会社ツムラ （ｚ）−リグスチリドの製造方法
US8247198B2 (en) 2007-09-21 2012-08-21 Friedrich Srienc Enzymatic processing in deep eutectic solvents
AU2008327436B2 (en) 2007-11-22 2013-09-05 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
US8022014B2 (en) 2008-03-26 2011-09-20 Shrieve Chemical Products, Inc. Deep eutectic solvents and applications
WO2010109544A1 (ja) 2009-03-27 2010-09-30 株式会社メドレックス 核酸を有効成分とする外用剤組成物
WO2011057209A1 (en) 2009-11-06 2011-05-12 Qlt, Inc. Acidic ophthalmic formulations
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
EP2773366B1 (en) 2011-11-04 2017-03-01 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EP2597099B1 (en) 2011-11-23 2018-08-15 King Saud University Deep eutectic solvent and method for its preparation
EP2740484A1 (en) 2012-12-05 2014-06-11 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin, hair and/or muccous membranes and their cosmetic or pharmaceutical compositions
FR3002452B1 (fr) 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
CN105434337B (zh) 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031105A1 (en) 2006-09-08 2008-03-13 Delaval Holdings Ab Polymeric guanidine salt-based germicides
JP2008184402A (ja) 2007-01-29 2008-08-14 Medorekkusu:Kk 外用剤用の低刺激性溶解助剤
WO2011056545A2 (en) * 2009-10-26 2011-05-12 Trustees Of Boston University Antimicrobial ionic liquids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dobler, D., et al., International Journal of Pharmaceutics, 2013, vol. 441, pp.620~627

Also Published As

Publication number Publication date
US11786597B2 (en) 2023-10-17
JP2020097633A (ja) 2020-06-25
WO2015066647A3 (en) 2015-06-18
JP2016535781A (ja) 2016-11-17
JP2019073561A (ja) 2019-05-16
US20190388545A1 (en) 2019-12-26
WO2015066647A9 (en) 2015-09-17
US20160263225A1 (en) 2016-09-15
WO2015066647A2 (en) 2015-05-07
CA2929630C (en) 2021-01-12
CA3100536A1 (en) 2015-05-07
JP6674058B2 (ja) 2020-04-01
EP3062819A4 (en) 2017-09-27
EP3062819B1 (en) 2021-12-22
ES2908345T3 (es) 2022-04-28
US10449254B2 (en) 2019-10-22
KR20160097202A (ko) 2016-08-17
US20240156964A1 (en) 2024-05-16
EP3062819A2 (en) 2016-09-07
CA2929630A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
KR102286115B1 (ko) 경피 약물 전달용 이온성 액체
EP2025337B1 (en) Pharmaceutical composition for external use
KR101321775B1 (ko) 고휘발성 실리콘을 함유하는 약제학적 제조물
JP2005501069A (ja) 爪における感染のｎｏでの処置
CN112004531B (zh) 两部分的生成一氧化氮的局部组合物
JP6796638B2 (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
Sharma et al. Blooming pharma industry with transdermal drug delivery system
Nnamani et al. Transdermal microgels of gentamicin
Elhabal et al. Enhancing photothermal therapy for antibiofilm wound healing: insights from graphene oxide-cranberry nanosheet loaded hydrogel in vitro, in silico, and in vivo evaluation
Aggarwal Preparation of hydrogels of griseofulvin for dermal application
US20190021988A1 (en) Enhanced transdermal delivery of active agents
CN101365433B (zh) 离子电渗疗法用制剂
Ashish et al. Formulation and evaluation of in situ gel containing ciprofloxacin hydrochloride in the treatment of periodontitis
Senff-Ribeiro et al. Effect of a new 1, 3, 4-thiadiazolium mesoionic compound (MI-D) on B16-F10 murine melanoma
KR20200051690A (ko) 국소 조성물
US20140343159A1 (en) Formulation of small adrenergic agonist salt forms in organic solvents
CN114588108B (zh) 含抗虫剂的油溶性溶液剂及其制备方法和应用
US20180169033A1 (en) Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery
Patil et al. A design of expert-based development and optimization of voriconazole-loaded aspasomal gel for topical delivery
CA2398723C (en) Pharmaceutical composition comprising carriers for products based on vitamin-e, papain and hyaluronidase
WO2021145795A2 (ru) Биоадгезивное антибактериальное средство, способ его изготовления (варианты)
CN107427436A (zh) 含有环吡酮的指甲油组合物
Söpper Development of mucoadhesive carrier systems for flavoring agents and cannabidiol
Ethiraj et al. FORMULATION AND EVALUATION OF TRANSDERMAL PATCHS OF DILTIAZEM HYDROCHLORIDE.
CN104922135B (zh) 一种曲安奈德-硝酸益康唑贴剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5